Analyzing the impact of new cigarette product standards on smoking cessation rates
Impact analysis to prepare the nation and states for potential cigarette product standards
This study looks at how banning menthol cigarettes and reducing nicotine levels might help more adults in the U.S. quit smoking, and it aims to help health departments and support services get ready for more people wanting to quit.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11128943 on NIH RePORTER |
What this research studies
This research investigates how proposed cigarette product standards, specifically a menthol ban and a nicotine reduction standard, could influence smoking cessation rates among adults in the U.S. The study aims to estimate the number of smokers who may quit as a result of these standards and to prepare state health departments and quitline operators for the potential increase in demand for cessation resources. By analyzing existing data and modeling outcomes, the research seeks to provide actionable insights for policymakers and health advocates to effectively support smokers in quitting.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult smokers, particularly those who use menthol cigarettes or are at higher risk for tobacco-related diseases.
Not a fit: Patients who do not smoke or are not interested in quitting smoking may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase smoking cessation rates and reduce tobacco-related diseases and deaths.
How similar studies have performed: Previous research has shown that similar regulatory approaches can lead to increased smoking cessation rates, indicating a promising potential for this study.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Carroll, Dana Mowls — University of Minnesota
- Study coordinator: Carroll, Dana Mowls
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.